Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Overview of attention for article published in BMC Medicine, December 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 14,868 followers.

Latest article in our Targeted Therapies #cancer collection: phase 2 #trial testing #toripalimab plus chemotherapy in stage II–III #NSCLC finds this combination to be both safe and effective. https://t.co/h6dphmqZpq Full collection here: https://t.co/

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab ... - BMC Medicine https://t.co/TfjSHI44gh

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in sta... https://t.co/joN1S8SrLr

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungM… https://t.co/7N7Vp3dneE https://t.co/Gl7aY91Gtz

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.